عربي
English
Quick links
Related sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Login area | Sign up
Forgot your password? Click here
Let us help you
Read about the latest topics.
Download the new version of the MOPH app 
 
 
 
Be Responsible
#Raise your voice
Send us any Fraudulent Action or Enquiry so we can ALL contribute to make a Difference

Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016* 
 
Chronic conditions Prevalence 
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension 47%
Diabetes 15%
Ulcers 10%
High cholesterol level 10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...) 8%
Diseases of the nervous system  3%
Epilepsy 3%
Thyroid Problems 2%
Asthma 2%
 *For previous years check the Statistical Bulletins' page 


Newly reported HIV cases, 2020



Newly reported HIV cases,2021



Newly reported HIV cases, 2022


New reported  HIV cases,2023



New reported  HIV cases,2024
https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

 
Number of Measles cases
 
 
2012
2013
2014
2015
 2016 2017 2018 2019 2020 2021 2022 2023
Measles
 9
 
1,760
 235
 
39
 44 126 952 1070 - 28 95 351
Source :MoPH 01/09/2024

Number of Tuberculosis cases*
Tuberculosis cases 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total number of cases 630 689 682 666 657 632 668 760 656 466 510 510 540
Number of Lebanese cases  330 341 337 312 305 271 254 288 277 233 263 249 225
Number of Non-Lebanese cases 300 348 345 354 352 361 414 472 379 233 247 261 315
*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024




 
 
 
    1
    ...
    46
    47
    48
    49
    50
    51
    ...
    190
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
ATC Name B/G Ingredients Dosage Form Price
J01DD04 MEGION-A G Ceftriaxone - 0.5g/2ml, Lidocaine (ampoule) - 0.5g/2ml Injectable powder + solvent 355,840 L.L
J01DD04 MEGION-A G Ceftriaxone - 1g/3.5ml, Lidocaine (ampoule) - 1g/3.5ml Injectable powder + solvent 623,468 L.L
L04AC02 SIMULECT BioTech Basiliximab - 20mg 20mg Injectable powder + solvent 137,661,787 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 75IU 75IU Injectable powder + solvent 16,423,597 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 150IU 150IU Injectable powder + solvent 41,777,992 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 900IU 900IU Injectable powder + solvent 25,830,983 L.L
L01CX01 TRABECTEDIN EVER PHARMA G Trabectedin - 1mg 1mg Injectable powder for concentrate for solution 88,574,985 L.L
L01XX02 SPECTRILA BioTech Asparaginase, recombinant - 10,000IU 10,000IU Injectable powder for concentrate for solution 21,370,813 L.L
L01FD04 ENHERTU BioTech Trastuzumab deruxtecan - 100mg 100mg Injectable powder for concentrate for solution L.L
L01AA09 BENDAMUSTINE HYDROCHLORIDE G Bendamustine HCl - 25mg/10ml 25mg/10ml Injectable powder for concentrate for solution 19,610,153 L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution L.L
L01AA09 BENDAMUSTINE MEDAC G Bendamustine HCl - 2.5mg/ml (25mg) 2.5mg/ml Injectable powder for concentrate for solution 24,934,922 L.L
L01AA09 RIBOMUSTIN B Bendamustine HCl - 100mg 100mg Injectable powder for concentrate for solution 31,939,807 L.L
L01AA09 BENDAMUSTINE HYDROCHLORIDE G Bendamustine HCl - 100mg/50ml 100mg/50ml Injectable powder for concentrate for solution 78,439,178 L.L
L01AA09 BENDAMUSTINE HYDROCHLORIDE PHARMINICIO G Bendamustine HCl - 100mg/50ml 100mg/50ml Injectable powder for concentrate for solution 78,439,178 L.L
L04AB02 IXIFI BioTech Infliximab - 100mg 100mg Injectable powder for concentrate for solution L.L
L01AA09 BENDAMUSTINE MEDAC G Bendamustine HCl - 2.5mg/ml (100mg) 2.5mg/ml Injectable powder for concentrate for solution 16,887,989 L.L
L01AC01 TEPADINA G Thiotepa - 100mg 100mg Injectable powder for concentrate for solution 98,197,306 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 300mg 300mg Injectable powder for concentrate for solution 152,492,033 L.L
L01BA04 PEMETREXED ACCORD G Pemetrexed (disodium) - 500mg 500mg Injectable powder for concentrate for solution 20,000,292 L.L
L01BA04 PEMITRA G Pemetrexed (disodium) - 500mg 500mg Injectable powder for concentrate for solution 47,161,032 L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution 295,038,213 L.L
A16AB07 MYOZYME BioTech Alglucosidase alfa, recombinant human acid - 50mg 50mg Injectable powder for concentrate for solution 56,536,307 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution 82,195,925 L.L
L04AB02 IXIFI BioTech Infliximab - 100mg 100mg Injectable powder for concentrate for solution 23,911,751 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 36,113,036 L.L
L01FD01 KANJINTI BioTech Trastuzumab - 420mg 420mg Injectable powder for concentrate for solution 79,305,881 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 100mg 100mg Injectable powder for concentrate for solution 135,545,977 L.L
L01FD03 KADCYLA BioTech Trastuzumab emtansine - 160mg 160mg Injectable powder for concentrate for solution 216,872,714 L.L
    1
    ...
    46
    47
    48
    49
    50
    51
    ...
    190
Sitemap
© Copyrights reserved to Ministry of Public Health 2026